Original research

Gut microbiome signatures of colorectal cancer development are more pronounced in women compared to men in a population-based screening cohort

Bucher-Johannessen, C. [1,2,3]*, *Kværner, AS.*[4]*, *Birkeland, E.*[5], *Botteri E.*[2,4], *Avershina, E.*[1,5], *Bemanian, V.*[6], *Hoff, G.*[4,7], *Randel, KR.*[4], *Hovig, E.*[1,3], *Berstad, P.*[4], *Rounge, TB.*[1,4,5]

**Shared first authorship*

Author Affiliations:

1 Department of Tumour Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway

2 Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway

3 Department of Informatics, University of Oslo, Oslo, Norway

4 Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health; Oslo, Norway

5 Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway

6 Department of Pathology, Akershus University Hospital, Lørenskog, Norway

7 Department of Research, Telemark Hospital, Skien, Norway

Corresponding Authors

Trine B. Rounge

Tel: +47 996 043 04

Mailing address: University of Oslo, Postbox 1068 Blindern, 0316 Oslo, Norway

E-mail address: trinro@uio.no

ORCID identifier: 0000-0003-2677-2722

Short running head: Sex, the gut microbiome and colorectal cancer

Abstract

Background: The gut microbiome has emerged as a promising source of biomarkers to enhance early detection of colorectal cancer (CRC). However, sex-specific differences in gut microbial profiles and their relationship to CRC risk remain underexplored.

Objective: To investigate sex-specific differences in gut microbial profiles of a CRC-screening population, as well as the potential for sex-specific associations between the gut microbiome and colorectal lesions.

Methods: This cross-sectional study included 1,034 faecal immunochemical test-positive screening participants aged 55-77 years recruited from the Norwegian CRCbiome study. Shotgun metagenomic sequencing was used to generate taxonomic and functional profiles of the gut microbiome, which were integrated with clinicopathological, demographic, and lifestyle data. Associations between sex, colorectal lesions, and microbial characteristics - including α-diversity, β-diversity, and abundances of bacterial species and functions - were assessed, including their interactions.

Results: Male participants had significantly higher odds of presenting with both non-advanced (OR: 1.50; 95% CI: 1.00-2.26) and advanced (OR: 1.46; 95% CI: 1.10-1.93) colorectal lesions compared to women. Gut microbial profiles differed markedly by sex, demonstrating compositional shifts and distinct bacterial profiles (13 bacteria and 41 functions more abundant in women, 19 taxa and 58 functions more abundant in men). In women, microbial α- and β-diversity varied across lesion subtypes, whereas no such differences were observed in men. Interaction analyses identified five bacteria and nine functions that were differentially associated with colorectal lesions by sex. Known CRC-associated bacteria showed broadly similar profiles in women and men, however, *pks*-positive *Escherichia coli* was associated with CRC in women only.

Conclusion: This study highlights sex-specific differences in the gut microbiome and their association with colorectal lesions, emphasising the need to take sex into account in future research aiming to enhance CRC prevention strategies and treatment.

Trial Registration: The BCSN is registered at clinicaltrials.gov (National clinical trial (NCT) no. 01538550).

Keywords: Sex, gut microbiome, effect modification, mediation, colorectal lesions, colorectal cancer, colorectal cancer screening

63 ## Introduction

64 Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
65 cancer-related deaths worldwide (1). Both CRC incidence and mortality show a male
66 predominance, a pattern that remains consistent across countries, despite significant variations
67 in incidence rates (2, 3). Variations in exposure to, and effects of, dietary and lifestyle factors are
68 likely contributors to the observed disparities (4); however, the extent of their contribution remains
69 unclear. Projections suggest that the observed sex disparities in CRC risk are likely to persist in
70 the coming decades (2).

71 CRC screening has the potential to reduce both CRC incidence (5-8) and mortality (5-12). Faecal
72 immunochemical testing (FIT) is the most widely used screening method (13), and is
73 recommended as the preferred test by EU guidelines (14). FIT detects haemoglobin in stool, with
74 positivity thresholds varying from >10 to >150 µg/g across European screening programs (15),
75 prompting follow-up diagnostic colonoscopy. While FIT has a good sensitivity for colorectal
76 cancers (16), it is less accurate for precancerous lesions (16) and lesions located in the proximal
77 colon (17). Additionally, FIT-based screening has been criticised for potentially disadvantaging
78 women (18). This may be due to anatomical, physiological, and/or pathogenetic differences
79 affecting diagnostic performance of either the FIT (19-23) or the colonoscopy (24-27).
80 Complementary strategies to improve screening efficacy and equity are needed.

81 Emerging evidence supports a role of the gut microbiome in CRC development (28-33). Proposed
82 mechanisms include interaction with the immune system (34-36), induction of inflammation and
83 oxidative stress (37-39), cross-talk with the endocrine system (40-42), and production of bioactive
84 compounds, including metabolites, toxins, and virulence factors (43-49). A growing number of
85 studies suggest that specific microbes — alone or in combination with other biomarkers — can
86 be used to predict colorectal lesions (50, 51), and in a recent study, we showed that microbial
87 signatures combined with quantitative FIT values can improve detection of premalignant lesions

in a real-world screening setting (52). As sex impacts the microbial profile (53-56), it is plausible that the microbiome's role in CRC development, as well as its potential as a biomarker source, varies by sex.

Our study provides an in-depth characterization of sex differences in gut microbial profiles and explores how these differences evolve with advancing CRC stage in a screening setting. Further, we examine whether the relationship between the gut microbiome and disease stage manifests differently in men and women, which is crucial for understanding the potential of the gut microbiome as a source of biomarkers in CRC screening.

Methods and materials

Study population

In this study, we used data from the CRCbiome study, which has been described in detail previously (57). The CRCbiome study was initiated in 2017 and invited participants from the large Bowel Cancer Screening in Norway pilot trial (BCSN) (n=139,291) (58). The BCSN started in 2012, where Norwegian citizens from selected municipalities surrounding the capital of Oslo (aged 50-74 years) were invited to either undergo once-only sigmoidoscopy or FIT test biennially. The CRCbiome study recruited participants from the FIT arm (rounds 2-4), using a positive FIT test as an inclusion criterion (≥15 µg haemoglobin/g faeces). Participants with a positive FIT test were referred to colonoscopy, where potential neoplastic lesions were removed. An information letter and two questionnaires, a lifestyle and demographic questionnaire (LDQ) and a food frequency questionnaire (FFQ), were sent out prior to scheduled colonoscopy. Participants were informed that by completing and returning either questionnaire, they provided consent and agreed to participate in the CRCbiome study. Samples were excluded from analyses if they had insufficient sequencing depth, defined as less than 1 gigabase of sequencing output after quality,

112 if the individuals did not attend follow-up colonoscopy or presented with one or two non-advanced
113 neoplastic lesions or serrated lesions during screening.
114 The BCSN trial and the CRCbiome study have been approved by the Regional Committee for
115 Medical and Health-related Research Ethics in Southeast Norway (REK ref: 2011/1272 and
116 63148, respectively. The BCSN trial was registered at clinicaltrials.gov (Clinical Trial (NCT) no.:
117 01538550).

118 **Outcome measures**

119 In this study, participants were classified into three colonoscopy groups: 1) "No neoplasia",
120 including individuals without lesions, those with ≥1 non-neoplastic lesion (e.g., inflammatory or
121 granulation tissue polyps), and those with other findings (e.g., diverticulitis, haemorrhoids, or IBD);
122 2) "Non-advanced neoplastic lesions, and 3) "Advanced lesions", which included those with ≥1
123 advanced serrated lesion, ≥1 advanced adenoma, or CRC. Here advanced adenoma was defined
124 as any adenoma with at least one of the following characteristics: villous histology (≥25% villous
125 components), high-grade dysplasia, or a polyp size ≥10 mm. Advanced serrated lesions were
126 defined as serrated lesions with a size ≥10 mm or evidence of dysplasia. CRC was defined as
127 the presence of adenocarcinoma originating in the colon or rectum (ICD-10 codes C18-20).

128 Questionnaire data

129 Lifestyle and demographic information was collected using a self-administered four-page
130 questionnaire, described in detail elsewhere (57). The questions relevant to the current study
131 captured data on demographic factors (national affiliation, education, employment status, and
132 marital status), clinical factors (family history of CRC and diagnosis of chronic bowel disorders),
133 and lifestyle factors (smoking and snus habits, and physical activity level).
134 Dietary intake data were obtained using a validated 14-page semi-quantitative FFQ, developed
135 and validated at the Department of Nutrition, University of Oslo (59-64). This FFQ assessed

136 habitual dietary intake over the preceding year and provided estimates of total energy intake,
137 macronutrient and micronutrient intake, as well as intake of foods and beverages (256 questions
138 in total). Dietary intake in grams per day was calculated using the dietary calculation system KBS
139 (short for "**K**ost**b**eregnings**s**ystem"). The most recent database at the time (AE-18) was used,
140 which is an extended version of the 2018 Norwegian Food Composition Table (65). The FFQ also
141 recorded self-reported body weight (kg) and height (cm), which were used to calculate body mass
142 index (BMI). Based on data from the two questionnaires, a seven-point diet and lifestyle score
143 was created to measure adherence to the 2018 World Cancer Research Fund (WCRF)/American
144 Institute for Cancer Research (AICR) cancer prevention recommendations. The
145 recommendations were operationalised using a standardised scoring system developed by
146 Shams-White *et al*. (66, 67), as described in detail elsewhere (68).

147 **Prescription drug data**

148 Dispensed prescription data within 12 months of study inclusion for each participant were
149 retrieved from the Norwegian Prescription Database (NorPD), which catalogues all prescriptions
150 in Norway using the Anatomical Therapeutic Chemical (ATC) system (69). The list included drugs
151 for common comorbidities: diabetes (≥2 dispensations of any drug with ATC code A10);
152 cardiovascular disease (≥1 of any with ATC codes C, and/or B01); chronic obstructive pulmonary
153 disease (≥1 of any with ATC codes 698 R03AC, R03AK, R03AL, R03BB, R03DA, R03DC,
154 R03DX, R03BA); and antibiotics (≥1 of any with 699 ATC codes J01, A07AA, or P01AB), since
155 they are of relevance to microbiome analyses.

156 **Sample collection and DNA extraction**

157 Participants were provided with at-home stool sampling kits suitable for FIT-measurement
158 analyses and were instructed to ship the sample by mail to the testing facility (estimated delivery
159 time 3-10 days). After FIT-measurement (testing for haemoglobin concentration), the leftover

160 sample was further stored at -80°C. Before DNA extraction, leftover FIT samples were buffered,
161 and 500 µL aliquots were used for analysis. DNA extraction utilised the QIAsymphony DSP
162 Virus/Pathogen Midikit (Qiagen, Hilden, Germany), according to the instruction manual, with
163 additional off-board lysis and bead-beating. Extracted DNA was buffered in 60 µl AVE buffer. DNA
164 from FIT tubes showed no detectable cross-contamination and harboured diverse microbial
165 communities (70, 71).

166 **Library preparation and sequencing**

167 Following extraction, sample quality was measured on a NanoDrop 2000 spectrophotometer
168 (Thermo Fisher Scientific, MA, USA) and DNA concentration using a Qubit Fluorometer (Thermo
169 Fisher Scientific, MA, USA). Samples with a DNA concentration above 0.7 ng/µl were considered
170 eligible for library preparation and sequencing. Library preparation was performed using the
171 Nextera DNA Flex Library Prep Reference Guide according to the manual, with the modification
172 of reducing the reaction volume to one-fourth of the reference. Sample pools were sequenced on
173 the Illumina NovaSeq system (Illumina Inc., CA, USA), resulting in 151 bp paired-end reads.
174 Library preparation and sequencing were performed at the FIMM Technology Centre in Helsinki,
175 Finland.

176 **Microbiome characterisation**

177 Sequencing reads were quality controlled using KneadData (v0.12)
178 (http://huttenhower.sph.harvard.edu/kneaddata) with default settings to remove adapters, low-
179 quality bases, and reads mapping to the human genome. MetaPhlAn4 (72) (v4.0.6) was used to
180 identify the relative abundance of microbial taxa and bacterial taxa for use in subsequent
181 analyses. Further, HUMAnN3 was used (73) (v3.7) to determine gene content using the
182 mpa_vOct22_ChocoPhlAn_202212 pangenome database and the UniRef90 (74) database for
183 classifying the gene families into Gene Ontology (GO) annotations (75, 76) covering biological

184 processes (BP), molecular functions (MF) and cellular components (CC) – hereafter collectively
185 referred to as functions. Abundance of gene content from HUMAnN3 was scaled by the number
186 of quality-assessed reads per million.

187 Targeted analyses were carried out for two sets of microbial constituents: Bacterial species
188 identified as associated with the presence of CRC both by us (52) and others (77), and *pks*-
189 stratified *E. coli*. To determine *pks* status, reads were aligned to the *pks* gene cluster (GenBank:
190 AM229678.1). Samples with MetaPhlAn4-detected *E. coli* and ≥10% coverage of the *pks* region
191 were classified as *pks*-positive, unless mapping showed an incomplete colibactin cluster.

192 **Statistics**

193 We summarised continuous variables using the median value with interquartile range and
194 categorical variables using counts with percentages. Within-group differences were examined
195 using Kruskal-Wallis or Wilcoxon rank sum test for continuous variables and Pearson`s Chi-
196 squared or Fisher`s exact test for categorical variables, as appropriate.
197 Missing data resulted from participants not returning or fully completing the questionnaires, or
198 whose responses were of insufficient quality. Therefore, to ensure complete datasets, multivariate
199 imputation by chained equations was performed using the R package *mice* (78). The imputed
200 variables included marital status, employment status, smoking status, and the WCRF/AICR score.
201 All variables listed in Table 1 were used as predictors in the imputation process. All analyses
202 reported in the manuscript are based on the imputed dataset.
203 We ran a multinomial logistic regression analysis to study the association between sex and
204 colonoscopy findings (i.e., a) no neoplasia (reference category); b) non-advanced neoplastic
205 lesions; and c) advanced lesions). The analysis was adjusted for the following covariates: Model
206 1) age (continuous) and screening centre (centre 1, centre 2); model 2: model 1 covariates,
207 employment status (employed, retired, other), marital status (not married/non-cohabiting,

208 married/cohabiting), smoking status (never smoked, ever smoked) and the WCRF/AICR score
209 (continuous). Covariates were selected based on the association patterns observed in Table 1
210 and Supplementary Table 1. Unless otherwise specified, the subsequent analyses were
211 conducted using these covariate sets.
212 To investigate microbial differences between sexes, α-diversity, β-diversity, and differential
213 abundance of bacterial species and functions were assessed. Differences in α-diversity indices
214 (Shannon and Inverse Simpson) were analysed using analysis of variance (ANOVA). β-diversity
215 differences were assessed using the Bray-Curtis dissimilarity index, calculated with the vegdist
216 function in the R package *vegan* (79) and tested for significance using permutational analysis of
217 variance (PERMANOVA) with 999 permutations. Differentially abundant taxa and functions were
218 identified using *MaAsLin2* (80) with the following settings: a minimum abundance threshold of
219 10%; log2 transformation with zero values replaced by a pseudo-count equal to half the lowest
220 observed value across all features; normalisation set to none for bacterial abundances and total
221 sum scaling for functions; and a linear model. Prior to analysis, functions strongly correlated with
222 bacterial species (Spearman's correlation coefficient > 0.5) were excluded to mitigate the risk of
223 spurious associations driven by bacterial variation. Differentially abundant species and functions
224 were adjusted for multiple testing using the Benjamini-Hochberg (BH) correction method.
225 To investigate sex-specific influences of the gut microbiome on colorectal lesions, sex-stratified
226 analyses were conducted for α-diversity, β-diversity, differential abundance of microbial species
227 and functions, presence or absence of CRC-associated species, and pks-stratified *E. coli*. For α-
228 and β-diversity, sex-specific associations were examined by including interaction terms for sex
229 and lesion status. Bacterial species and functions that were differentially abundant between no
230 neoplasia and advanced lesions at a BH-corrected p-value of 0.2, in either men or women, were
231 further analysed for interaction effects in the entire dataset using multinomial logistic regression
232 with interaction terms of sex and the log-transformed abundance values. Evaluation of CRC-
233 associated species was performed by sex-stratified logistic regression models contrasting no

234 neoplasia with CRC, using the presence or absence of each CRC-associated species as the
235 independent variable. Any *E. coli* detection and p*ks*-stratified *E. coli* was evaluated in a
236 multinomial logistic regression model contrasting no neoplasia with non-advanced neoplastic
237 lesions and advanced lesions, and a separate logistic regression model contrasting no neoplasia
238 with CRC, performed independently in each sex.
239 To address potential sex-related differences in lesion subtype and location, sex-stratified α- and
240 β-diversity analyses were performed comparing individuals with advanced serrated lesions to
241 those without neoplasia, and by lesion localisation. Sensitivity analyses were also performed
242 without including individuals with: advanced serrated lesions, inflammatory bowel disease (IBD)
243 diagnosed during colonoscopy, and self-reported consumption of antibiotics within the last 3
244 months prior to study inclusion.
245 All analyses were performed using the R statistical environment with the main packages *tidyverse*
246 (81) (v1.3.1), *rstatix* (82) (v0.7.0), *nnet* (83) (v7.3-16), *mice* (78) (v3.14.0), *vegan* (79) (v2.5.7),
247 and *MaAsLin2* (80) (v1.12.0).
248

Results

Characteristics of the study population overall and by sex

Participants' characteristics overall and stratified by sex are presented in Table 1. The study included more men (n=582; 56%) than women (n=452; 44%). Men were more likely to be married, possess a university degree, and be employed, whereas women more frequently reported bowel disorders. In terms of lifestyle factors, men were more likely to use tobacco snus, have a higher BMI, and lower adherence to cancer prevention recommendations compared to women. Similar patterns were also observed in the control group alone (Supplementary Table 1). No difference in lesion location (proximal versus distal) was observed between men and women. However, there was a significant difference in lesion subtypes, women more often presenting with advanced serrated lesions than men. In both sexes, the presence of screen-detected lesions (whether non-advanced or advanced) was associated with older age, being retired, being unmarried or not cohabiting, being screened at Bærum Hospital and having a higher alcohol consumption (Supplementary Table 2). Differences in comorbidity-related prescriptions across colonoscopy groups were seen for haemorrhoid and cardiovascular medications in men, and for type 2 diabetes mellitus (T2DM) drugs in women (Supplementary Table 3). In both sexes, individuals without neoplasia more frequently reported IBD (Supplementary Table 3). Supplementary Table 4 shows the associations between sex and colonoscopy findings. Compared to women, men were more likely to present with non-advanced neoplastic lesions and advanced lesions, with odds ratios (ORs) of 1.55 (95% confidence interval (CI): 1.05, 2.29) and 1.47 (95% CI: 1.12, 1.92), respectively. Additional adjustment for lifestyle and demographic factors only modestly attenuated the effect estimates (ORs of 1.50 (95% CI: 1.00, 2.26) and 1.46 (95% CI: 1.10, 1.93), respectively).

Table 1. Participants' characteristics overall (n=1,034) and among women (n=452) and men (n=582)[1].

Variables	n	Women[1] (n = 452)	Men[1] (n = 582)	Overall[1] (n = 1,034)	p-value[2]
Age, years	1,034	67 (62, 72)	67 (62, 72)	67 (62, 72)	0.901
Screening center, n (%)	1,034				0.830
Moss		250 (55)	318 (55)	568 (55)	
Bærum		202 (45)	264 (45)	466 (45)	
National affiliation, n (%)	989				0.285
Norwegian		415 (94)	504 (92)	919 (93)	
Non-norwegian		27 (6.1)	43 (7.9)	70 (7.1)	
Family history of CRC, n (%)	923	87 (21)	98 (19)	185 (20)	0.506
Localisation	584				0.821
Distal only		61 (26)	89 (25)	150 (26)	
Any proximal		170 (74)	264 (75)	434 (74)	
Advanced serrated lesions	584				**0.031**
Yes		60 (26)	64 (18)	124 (21)	
No		171 (74)	289 (82)	460 (79)	
Marital status, n (%)	1,013				**<0.001**
Not married/non-cohabiting		121 (27)	81 (14)	202 (20)	
Married/cohabiting		326 (73)	485 (86)	811 (80)	
Education, n (%)	1,008				**0.021**
Primary school		102 (23)	94 (17)	196 (19)	
High school		174 (39)	219 (39)	393 (39)	
University/college		168 (38)	251 (45)	419 (42)	
Employment status, n (%)	1,015				**0.002**
Employed		119 (27)	203 (36)	322 (32)	
Retired		259 (58)	307 (54)	566 (56)	
Other		69 (15)	58 (10)	127 (13)	
Bowel disorder, n (%)	1,002				**0.001**
No bowel disease		357 (82)	501 (89)	858 (86)	
Any disorder		81 (18)	63 (11)	144 (14)	
Inflammatory bowel disease	1,034				0.861
Yes		10	15	25	
No		442	567	1009	
Smoking status, n (%)	1,013				0.384
Never smoked		173 (39)	204 (36)	377 (37)	
Ever smoked		274 (61)	362 (64)	636 (63)	
Snus status, n (%)	971				**<0.001**
Non-snuser		412 (99)	489 (88)	901 (93)	
Snuser[3]		6 (1.4)	64 (12)	70 (7.2)	
Energy intake, kcal/day	1,007	1,914 (1,572, 2,374)	2,399 (1,912, 2,900)	2,181 (1,733, 2,717)	**<0.001**
Alcohol intake, g/day	1,007	5 (1, 12)	12 (4, 24)	9 (2, 19)	**<0.001**
BMI, kg/m^2	1,000	25.9 (23.1, 28.8)	27.1 (24.6, 29.3)	26.5 (24.1, 29.3)	**<0.001**
Physical activity, min/week	1,015	135 (0, 300)	105 (0, 360)	105 (0, 300)	0.354
Recent antibiotic use, n (%)[4]	964	69 (16)	67 (12)	136 (14)	0.097
WCRF/AICR score, points[5]	943	2.5 (2.0, 3.0)	2.3 (1.8, 2.8)	2.5 (2.0, 3.0)	**<0.001**
Sequencing depth	1,034	12,921,349	13,116,130	13,030,984	0.416

[1]*Values are median (IQR) for continuous variables and n (%) for categorical variables.*

[2]P-values are derived from Wilcoxon rank-sum test, Students t-test, Pearson`s Chi-squared testing, as appropriate.
[3]To be defined as a snuser one had to be a regular or occasional user or having quit consumption within the last ten years.
[4]Recent antibiotic use was defined based on self-reported use of antibiotics within 3 months of sample collection.
[5]WCRF/AICR score was a seven point score that measured adherence to the World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) cancer prevention recommendations.
Abbreviations: AICR; American Institute of Cancer Research, BMI; Body mass index, CRC; colorectal cancer, g; gram, n; number of participants in a group, WCRF; World Cancer Research Fund

Sex and the gut microbiome

Among the 1,034 included participants, the mean (SD) number of paired-end reads was 13,030,984 (3,883,470). A total of 2,756 bacterial species were identified, with a mean (SD) of 239 (68) species per sample, with means (SD) of 241 (66) and 237 (69) in men and women, respectively.

<u>α- and β-diversity</u>

Associations of sex with α- and β-diversity are illustrated in Figure 1A-B. There were no associations between sex and the two α-diversity indices (neither Shannon nor the Inverse Simpson index, ANOVA $P > 0.05$, Figure 1A). However, notable differences in β-diversity were observed between the sexes both in the control group (PERMANOVA, $P = 0.002$, $R2 = 0.004$, Supplementary Figure 1) and the population as a whole (PERMANOVA, $P = 0.001$, $R2 = 0.003$, Figure 1B), which were attenuated, but remained statistically significant after adjusting for lifestyle and demographic factors (PERMANOVA, $P = 0.001$, $R2 = 0.002$).



Figure 1: Sex-related differences in gut microbial profiles. (A) Within-sample α-diversity, measured by the Inverse Simpson (left) and Shannon (right) indices, in women and men. (B) Between-sample β-diversity visualized by principal coordinates analysis (PCoA) of

301 Bray–Curtis dissimilarity. Differences between sexes were assessed using PERMANOVA; corresponding
302 R^2 values and p-values are shown in the plot. (C–D) Differentially abundant bacterial species (C) and
303 microbial functions (D) between women and men identified by MaAsLin2 analyses. Effect estimates are
304 shown as $\log_2$ fold-change (Log_2FC) with 95% confidence intervals (CI). Species were included if
305 Benjamini–Hochberg adjusted p-values were < 0.05; for microbial functions, the 32 features with the most
306 extreme Log_2FC in either direction are displayed (full results in Supplementary Data 1). Features enriched
307 in men are shown in red; those enriched in women are shown in blue. All models were adjusted for age
308 (continuous), screening centre (Moss, Bærum), employment status (employed, retired, other), marital
309 status (married/cohabiting, not married/non-cohabiting), smoking status (never, ever), and the continuous
310 WCRF/AICR score. Names of the following functions have been truncated in D): [BP] negative regulation
311 of fatty acid biosynthetic process; [MF] oxidoreductase activity, acting on the aldehyde or oxo group of
312 donors, disulfide as acceptor; [MF] mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity.
313 Abbreviations: BP; biological process, CC; Cellular Components, MF; Molecular Function.
314

315 Differentially abundant bacteria and functions

316 In total, 52 bacterial species were differentially abundant between women and men (P*adj* < 0.05).
317 Of these, 32 (62%) species remained statistically significant after adjusting for lifestyle and
318 demographic factors (Figure 1C, Supplementary Data 1). Thirteen were more abundant in women
319 and 19 in men. The strongest associations with male sex were observed for *Paraprevotella clara*
320 and *Bifidobacterium adolescentis*. In contrast, the species most strongly associated with female
321 sex were *Eggerthella lenta* and *Streptococcus thermophilus*. At the functional level, 174 functions
322 were differentially abundant between the sexes (P*adj* < 0.05). Of these, 99 (57%) remained
323 statistically significant after adjusting for lifestyle and demographic factors (Figure 1D,
324 Supplementary Data 1), with 41 functions more abundant in women and 58 in men. In women,
325 functions with the largest log2 fold-change (Log2FC) were guanidinobutyrase activity (MF), Smc5-
326 Smc6 complex (CC), and N-methylhydantoinase (ATP-hydrolyzing) activity (MF). In men, the

327 functions with the largest effect sizes were negative regulation of fatty acid biosynthetic processes

328 (BP), uroporphyrinogen III biosynthetic processes (BP) and hyaluronic acid binding (MF).

329


A
InvSimpson
Shannon
Women
Men
B
Women
R2 = 0.006
p = 0.007
PCoA1 (7.6%)
PCoA2 (4.5%)
C
Men
R2 = 0.004
p = 0.2
PCoA1 (6.9%)
PCoA2 (4.7%)
No neoplasia
Non−advanced neoplastic lesion
Advanced lesion
D
Men
Advanced lesion
Women
Advanced lesion
GGB51647_SGB4348
Faecalibacterium prausnitzii
GGB79634_SGB101324
GGB52130_SGB14966
Oscillospiraceae bacterium.
Lachnospiraceae bacterium
Victivallis lenta
Blautia obeum
Parabacteroides distasonis
Hungatella hathewayi
Ruthenibacterium lactatiform.
Flavonifractor plautii
Eggerthella lenta
Enterocloster bolteae
E
[MF] 1−phosphofructokinase activity
[BP] tetracenomycin C biosynthetic process
[BP] DNA restriction−modification system
[MF] 1,4−alpha−glucan branching enzyme activity
[BP] peptidyl−L−beta−methylthioaspartic acid b...
[MF] aspartate−tRNA ligase activity
[MF] trans−2−enoyl−CoA reductase (NAD+) activity
[MF] 1,4−alpha−glucan branching enzyme activity...
[MF] pyruvate kinase activity
[MF] amidophosphoribosyltransferase activity
[MF] benzene 1,2−dioxygenase activity
[MF] tartrate dehydrogenase activity
[BP] regulation of GTPase activity
[MF] protein disulfide oxidoreductase activity
[MF] hydrolase activity, acting on ester bonds
[CC] cell
[BP] cell redox homeostasis
[BP] deoxyribonucleotide biosynthetic process
[MF] dihydrolipoyl dehydrogenase activity
[MF] dipeptidyl−peptidase activity
[BP] cellular aromatic compound metabolic process
[MF] hydrolase activity, acting on acid anhydrides
[MF] tetrahydrodipicolinate N−acetyltransferase activity
q-value
q < 0.2
ns
Interaction
ns
sign

330

331 **Figure 2. Sex-stratified analyses of gut microbial profiles across colonoscopy findings.**
332 (A) Within-sample α-diversity, measured by the Inverse Simpson (upper) and Shannon (lower) indices,
333 across colonoscopy groups—no neoplasia (NN), non-advanced neoplastic lesions (NANL), and advanced
334 colorectal lesions (AL)—in women and men. (B–C) Between-sample β-diversity visualized by PCoA of
335 Bray–Curtis dissimilarity for women (B) and men (C). (D–E) Differentially abundant bacterial species (D)
336 and microbial functions (E) across colonoscopy groups in women and men. Effect estimates comparing AL
337 to NN are shown as Log_2FC with 95% CI. Species and functions were selected for visualization based on
338 Benjamini–Hochberg adjusted p-values < 0.2 and < 0.15, respectively, in either sex (all features with p <
339 0.2 are listed in Supplementary Data 2). Triangles denote significant interactions between sex and
340 abundance of species/functions identified by multinomial logistic regression (p < 0.05). All models were
341 adjusted for age (continuous), screening centre (Moss, Bærum), employment status (employed, retired,
342 other), marital status (married/cohabiting, not married/non-cohabiting), smoking status (never, ever), and
343 the continuous WCRF/AICR score. Names of the following species and functions have been truncated in
344 D): *Oscillospiraceae bacterium Marseille-Q3528* and E): 1,4-alpha-glucan branching enzyme activity (using
345 a glucosylated glycogenin as primer for glycogen synthesis); peptidyl-L-beta-methylthioaspartic acid
346 biosynthetic process from peptidyl-aspartic acid. Abbreviations: sign; significant, ns; non-significant, BP;
347 biological process, CC; Cellular Components, MF; Molecular Function.
348

349 <u>Potential interactions between sex, the gut microbiome, and colorectal lesions</u>

350 To evaluate whether the association between the gut microbiome and colorectal lesions differed
351 by sex, sex-stratified analyses were performed for the following microbial measures: 1) α-
352 diversity, 2) β-diversity, and 3) taxonomic and functional profiles. For all measures, notable sex
353 differences were observed. Among women, significant differences in both α- and β-diversity were
354 identified between colonoscopy groups (Figure 2A-B). Women with non-advanced neoplastic
355 lesions had lower α-diversity compared to those without findings, while women with advanced
356 lesions had higher α-diversity (ANOVA, P < 0.05 for all comparisons, Figure 2A). Additionally,
357 distinct separation among colonoscopy groups was observed in the PCoA plot (PERMANOVA, *P*

358 = 0.007, R^2 = 0.006, Figure 2B). Conversely, no significant differences in α- or β-diversity were
359 observed across colonoscopy groups in men (Figure 2A and C). When examining advanced
360 lesions by location (no lesion vs. proximal, distal, or both), women showed a clear but non-
361 significant separation between groups, particularly between no lesion and distal lesions. This
362 pattern was less pronounced in men (Supplementary Figure 2); however, combined analyses
363 showed no statistically significant interaction effect (P = 0.066, P = 0.171, and P = 0.530, for the
364 Shannon, Inverse Simpson, and Bray-Curtis index, respectively). Sensitivity analyses excluding
365 participants with serrated lesions, IBD diagnosed during colonoscopy examination, or self-
366 reported antibiotic use within 3 months of colonoscopy yielded similar results to the overall
367 analyses.
368 For bacterial and functional abundance, a sex-specific pattern emerged when comparing no
369 neoplasia and advanced lesions. In women, 12 bacteria and 39 functions were differentially
370 abundant between groups, whereas 2 bacteria and 18 functions were differentially abundant in
371 men (P*adj* < 0.2, Figure 2D, Supplementary Data 2). Among the identified species, five
372 (*GGB52130 SGB14966*, *Enterocloster bolteae, Faecalibacterium prausnitzii, GGB51647*
373 *SGB4348,* and *Flavonifractor plautii*) were confirmed to be sex-specific in multinomial logistic
374 regression analyses (interaction terms P < 0.05). Notably, *E. lenta* and *Hungatella hathewayi* were
375 inversely associated with advanced lesions regardless of sex. Among the differentially abundant
376 functions, nine were confirmed to be sex-specific in multinomial logistic regression analyses
377 (interaction terms P < 0.05), including two related to biological processes (peptidyl-L-beta-
378 methylthioaspartic acid biosynthetic process from peptidyl-aspartic acid, regulation of GTPase
379 activity), and seven related to molecular functions related to glycogen biosynthesis (1,4-alpha-
380 glucan branching enzyme activity, 1,4-alpha-glucan branching enzyme activity (using a
381 glycosylated glycogenin as primer for glycogen synthesis)), and small molecule degradation
382 (benzene 1,2-dioxygenase activity, tartrate dehydrogenase activity, hydrolase activity, acting on
383 ester bonds, dipeptidyl-peptidase activity, and hydrolase activity, acting on acid anhydrides).

384

385 Evaluation of previously reported CRC-associated species in women and men

386 When evaluating the presence or absence of previously CRC-associated (77) and validated (52)
387 bacterial species (n = 9) in sex-stratified models (Figure 3A, Supplementary Table 5), effect
388 estimates were broadly similar between men and women. All species but one (*F. nucleatum*) were
389 significantly associated with CRC in at least one sex-stratified analysis. For women, *Gemella*
390 *morbirollum*, *Peptostreptococcus stomatis,* and one SGB belonging to *F. nucleatum* was
391 significantly associated with CRC. In men, *Dialister pneumosintes*, the uncharacterized
392 SGB14305, *Alistipes ihumii*, *Porphyromonas somerae*, and *Porphyromonas uenonis* were
393 significantly associated with CRC. In women, the prevalence of three CRC-associated species
394 was very low; an overview of the prevalence of all the bacteria in men and women separately can
395 be found in Supplementary Table 5. In a recent analysis, we identified *E. coli* as being associated
396 with colorectal lesions in a *pks*-dependent manner (52). In analyses of *E. coli* detection (Figure
397 3B), the direction and magnitude of effect estimates were largely consistent between sexes, but
398 significance levels differed. In women, *pks*-negative *E. coli* was significantly associated with non-
399 advanced neoplastic lesions, and *pks*-positive *E. coli* was significantly associated with CRC. In
400 men, both overall *E. coli* detection and *pks*-negative *E. coli* were significantly associated with non-
401 advanced neoplastic lesions and advanced lesions. No significant interaction between sex and *E.*
402 *coli* status was observed (interaction term $P > 0.05$ for all comparisons)



Figure 3: Sex-stratified associations of previously CRC-linked bacteria including *E. coli* detection and *pks*-status.

(A) Odds ratios (log scale) from sex-stratified logistic regression models comparing participants with no neoplasia to those with CRC for previously reported CRC-associated bacterial species (77) validated in CRCbiome (52). Triangles denote associations significant at $P < 0.05$. *Odds ratio and CI are not displayed for women due to low prevalence across groups. (B) Odds ratio from regression models assessing associations between *E. coli* detection status (any *E. coli* (top), *pks*-negative *E. coli* (middle), and *pks*-positive *E. coli* (bottom) and lesion type (logistic regression for non-advanced neoplastic lesions, advanced lesion, and a multinomial logistic regression for CRC), shown separately for men and women. The reference group was participants with no neoplasia. Triangles denote associations significant at $P < 0.05$. All models were adjusted for age (continuous), screening centre (Moss, Bærum), employment status (employed, retired, other), marital status (married/cohabiting, not married/non-cohabiting), smoking status (never, ever), and the continuous WCRF/AICR score.

417 ## Discussion

418 Recent work from our group, conducted in a large CRC screening-relevant cohort, demonstrated
419 that microbiome signatures add a modest but significant increase in prediction value for detecting
420 colorectal lesions (52), similar to other studies (48, 84-86). Yet, despite growing evidence that
421 host factors influence the microbiome, especially in disease, sex-specific differences in the gut
422 microbiome have remained largely unexplored. In this study, including metagenomes from >1000
423 CRC screening participants, we show that sex may serve as an effect modifier, where microbial
424 associations with advanced colorectal lesions were stronger in women than in men. Still, CRC-
425 associated bacteria did not show evidence of being sex-specific.

426 The CRCbiome study, including FIT-positive participants recruited from the large Norwegian
427 colorectal screening trial BCSN, showed that men had a significantly higher odds of presenting
428 with both non-advanced neoplastic lesions (55%) and advanced lesions (47%) at follow-up
429 colonoscopy, consistent with previous reports (21), including results from BCSN (15, 58). The
430 presence of advanced lesions is strongly linked to modifiable risk factors (87-89), as also
431 documented in our cohorts (68, 90-93). It has been suggested that the association between male
432 sex and CRC risk, at least in part, is caused by these factors (40, 94). However, the current study
433 and those from a large German screening cohort (n=15,985(95)) suggest that a large part of the
434 excess risk of advanced neoplasia among men cannot be explained by known modifiable risk
435 factors and that these alone are insufficient to explain the sex gap in CRC risk. On the other hand,
436 the higher occurrence of lesions in men could partially be attributed to FIT being less efficient in
437 women. Therefore, sex-specific FIT thresholds have been suggested (23), but adjusting FIT
438 thresholds is not straightforward (20, 21, 23, 96), highlighting the need for complementary
439 strategies

440 Similarly, we show that disparities in microbial profile between men and women are not solely
441 attributable to differences in exposure profiles. After adjusting for key lifestyle and demographic

442 factors known to contribute to microbial variation, a large part of the sex-microbiome associations
443 remained, suggesting that intrinsic factors are influential. Hormonal influence on the gut
444 microbiome is supported by evidence showing that microbial differences between sexes appear
445 in young adults and decline after age 50 (97) . Further, oestrogens are known to exhibit anti-
446 inflammatory properties, potentially modulating the gut environment and influencing cancer risk
447 differently in men and women, whereas androgens seem to exacerbate cancer development (40).
448 Indeed, the role of sex hormones in CRC development has been demonstrated in mice (98, 99).
449 Distinct sex-specific microbial profiles have been reported (56, 115-118), including investigations
450 within CRCbiome that have linked alcohol consumption to microbial variation by sex (91). We
451 have also previously reported that men in CRCbiome have a higher abundance of *P.*
452 *succinatutens* (100) and have identified CRC associations for bacteria of the
453 *Phascolarctobacterium* genus across populations (100-102). In the present study, we identified
454 32 bacterial species that were differentially abundant between men and women. Here, we found
455 that *B. adolescentis* levels were higher in men. This species has previously been found to be
456 elevated in older male CRC patients (103) and has been proposed as a probiotic due to its pro-
457 androgenic activity (104). In line with previous reports, we observed a higher abundance of *E.*
458 *lenta* and *G. pamelae* in women (97, 105). Both species potentially play a role in host physiology
459 and hormonal homeostasis via corticoid conversion to progestin (106). *E. lenta* has also been
460 reported as being increased in women with premature ovarian insufficiency (107). The hormone-
461 related *E. lenta* was the only species identified as both sex-specific and linked to the presence of
462 lesions.
463 When examining microbial profiles separately in men and women, we observed that women
464 exhibited clear differences in both α- and β-diversity across colonoscopy groups and lesion
465 localisation, whereas no such pattern was observed in men. Previous studies have suggested
466 sex differences in microbial profiles across controls, non-advanced neoplastic lesions, and CRC,
467 with *Liao* et al. (108) also reporting greater variation in women during CRC development.

468 However, these studies have been limited to a small sample size (N < 90), low taxonomic
469 resolution, or lack thorough description of participant inclusion (108-111). Therefore, to our
470 knowledge, our study is the first large-scale investigation within a population-based screening
471 setting to demonstrate sex-specific differences in the microbiome across colorectal lesion
472 subtypes.

473 We observed nominally significant, sex-specific associations for several bacterial species and
474 microbial functions. Five species, including *F. plautii*, *E. bolteae*, and *F. prausnitzii*, were
475 associated with advanced lesions in a sex-specific manner, with the effect size in directions
476 opposite to those reported previously (77). In our recent work (52), we proposed that these taxa
477 may reflect alternative causes of intestinal bleeding rather than being lesion-specific. One study
478 found that older age, female sex, smoking, alcohol consumption, higher BMI, and haemorrhoids
479 were associated with increased odds of false-positive FIT results in a screening population (112).
480 However, such factors, including other lifestyle factors and comorbidity profiles, were comparable
481 between sexes in our cohort, apart from a higher percentage of women with no neoplasia having
482 a prescription for medication indicating type 2 diabetes mellitus (T2DM). Although T2DM and
483 diabetes medication can influence the microbiome (113), the number of female participants with
484 prescriptions for diabetes medication in this cohort remains small. Together, these observations
485 suggest that intrinsic biological differences rather than external confounders are the primary
486 drivers of the sex-specific microbiome patterns we observed.

487 We have previously verified and reproduced the association between certain bacteria, which have
488 consistently been linked to CRC (77, 114). While significance levels varied, effect sizes for these
489 taxa, including *F. nucleatum* and *G. morbillorum,* were largely comparable in men and women.
490 These findings suggest that these CRC-associated species appear largely comparable between
491 sexes. Interestingly, *pks*-positive *E. coli* was significantly associated with CRC among women.
492 Most earlier studies have not investigated sex-specific effects of *pks* status on CRC development

493 (114, 115). Our results point to a possible sex-related dimension of *pks* role in CRC that should
494 be further researched.
495 A major strength of our study is the extensive microbiome dataset, combined with clinically verified
496 outcome data, enabling a thorough assessment of screening-relevant outcomes with minimal risk
497 of misclassification. Additionally, access to detailed lifestyle and demographic data enabled robust
498 covariate adjustments, distinguishing our study from most prior investigations on this topic (108,
499 109, 116). However, several limitations must be acknowledged. First, the cross-sectional design
500 prevents causal interpretations. Second, participation required enrolment in two consecutive
501 studies: first, the BCSN, followed by CRCbiome, potentially introducing selection bias. In the
502 BCSN, certain discrepancies existed in participant characteristics between men and women. For
503 men, non-participation was linked to younger age and not living with a partner, whereas for
504 women, it was associated with living farther from the screening centre (117, 118). Third, while our
505 comprehensive covariate adjustments strengthen the study, the possibility of residual
506 confounding cannot be ruled out.
507 The microbial variability observed across lesion subtypes in women, suggests that microbial
508 biomarkers might be particularly effective in women, for whom FIT performance is suggested to
509 be suboptimal. Incorporating microbial markers alongside FIT could reduce false positives and
510 ultimately make screening more equitable across sexes. Our study underscores the importance
511 of validating microbial biomarkers across diverse populations. Beyond CRC, understanding sex-
512 related microbial differences may also have broader implications for other gastrointestinal
513 conditions, including IBD and IBS.
514 To conclude, in this FIT-positive CRC screening population, our results indicate that sex modifies
515 the association between the microbiome and early stages of colorectal lesions, independent of
516 major lifestyle and demographic factors. This includes marked sex differences in microbial
517 diversity and composition, with 32 bacterial taxa, and 99 functional pathways differing between
518 women and men. Notably, we observed significant microbial differences, including *E. coli pks*

519 status, across lesion subtypes in women, but not in men. Our results underscore the importance
520 of considering sex in research investigating the gut microbiome-colorectal lesion axis, with
521 implications for biomarker discovery and tailoring personalised CRC prevention, detection, and
522 therapy.

523 **Abbreviations**

524 ACME: Average causal mediation effect

525 ADE: Average direct effect

526 AICR: American Institute for Cancer Research

527 ANOVA: Analysis of variance

528 ASV: Amplicon sequence variant

529 BCSN: Bowel Cancer Screening in Norway

530 BH: Benjamini-Hochberg

531 BMI: Body mass index

532 CI: Confidence interval

533 CRC: Colorectal cancer

534 FFQ: Food frequency questionnaire

535 FIT: Fecal immunochemical test

536 GO: Gene ontology

537 KBS: Kostberegningssystem

538 MaAsLin: Microbiome multivariable associations with linear models

539 NCT: National clinical trial

540 OR: Odds ratio

541 PCoA: Principal coordinate analysis

542 PERMANOVA: Permutational multivariate analysis of variance

PPV: Positive predictive value

SD: Standard deviation

TE: Total effect

TSS: Total sum scaling

WCRF: World Cancer Research Fund

Declarations

Ethics approval and consent to participate

The BCSN trial and the CRCbiome study have been approved by the Regional Committee for Medical and Health-related Research Ethics in Southeast Norway (REK ref: 2011/1272 and 63148, respectively). All participants provided written informed consent.

Consent for publication

Not applicable

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the database Federated EGA under accession code EGAS50000000170. Due to the sensitive nature of the data derived from human subjects, including personal health information, analyses, and sharing of data from this project must comply with the General Data Protection Regulation (GDPR). How to get access to the data is described here: https://www.mn.uio.no/bils/english/groups/rounge-group/crcbiome/. R-scripts used in this study are available at: https://github.com/Rounge-lab/sex-differences

Competing interests

564 The authors declare that they have no competing interest.

565 **Funding**

566 This project was made possible by funding from the Norwegian Cancer Society (grant
567 nos. 190179 and 198048), the Norwegian Cancer Society's umbrella organization for
568 cancer research (Kreftforeningens paraplystiftelse for kreftforskning), the Research
569 Council of Norway (grant no. 280667), and the South-Eastern Norway Regional Health
570 Authority (grant nos. 2022067 and 2020056). The BCSN trial study was funded by the
571 Norwegian Parliament (Norwegian national budget from 2011). The bowel preparation
572 used for colonoscopy was provided free of charge by Ferring Pharmaceuticals. The
573 funders had no role in study design, data collection, analysis, interpretation, or the writing
574 of this article.

575 **Author contributions**

576 TBR and PB were responsible for the conception and design of the study. ASK, CBJ, and EB
577 analysed the data. VB performed the sample preparation and lab work. ASK, CBJ, EB, EA, EB,
578 PB, and TBR interpreted the data. ASK and CBJ drafted the manuscript. All authors have
579 revised, commented on, and approved the final submitted manuscript.

580 **Acknowledgements**

581 We would like to acknowledge Jan Inge Nordby for his contribution to sample preparation and lab
582 work. Library preparation and sequencing were performed at the FIMM Technology Centre
583 supported by HiLIFE and Biocenter Finland. We would especially like to thank Harri A. Kangas,
584 and Pekka J. Ellonen. Finally, we want to thank our project coordinator Maja Sigerseth Jacobsen.
585

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

2. Global Cancer Observatory. Cancer Tomorrow | IARC - https://gco.iarc.who.int/tomorrow [Internet]. [Available from: https://gco.iarc.fr/tomorrow/en/dataviz/trends?types=0_1&sexes=1_2&mode=population&group_populations=0&multiple_populations=1&multiple_cancers=1&cancers=8_41&populations=900&apc=cat_ca20v1.5_ca23v-1.5&group_cancers=1.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

4. Baraibar I, Ros J, Saoudi N, Salva F, Garcia A, Castells MR, et al. Sex and gender perspectives in colorectal cancer. ESMO Open. 2023;8(2):101204.

5. Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299–311.

6. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345–57.

7. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310–22.

8. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606–15.

9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365–71.

10. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–71.

11. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008;95(8):1029–36.

12. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472–7.

13. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637–49.

14. Council of the European Union. Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC. Off J Eur Union. 2022;100:1–10.

15. Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B, et al. Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. Aliment Pharmacol Ther. 2025;61(1):122–31.

16. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020;158(2):418–32.

17. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer. 2011;104(11):1779–85.

18. Hultcrantz R. Aspects of Colorectal cancer screening, methods, age and gender. J Intern Med. 2020.

19. Brenner H, Haug U, Hundt S. Sex Differences in Performance of Fecal Occult Blood Testing. 2010;105(11):2457–64.

20. Brenner H, Qian J, Werner S. Variation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age: results from a large screening cohort. Clin Epidemiol. 2018;10:381–9.

21. White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC cancer. 2018;18(1):906.

22. Njor SH, Rasmussen M, Friis-Hansen L, Andersen B. Varying fecal immunochemical test screening cutoffs by age and gender: a way to increase detection rates and reduce the number of colonoscopies. Gastrointest Endosc. 2022;95(3):540–9.

23. Grobbee EJ, Wieten E, Hansen BE, Stoop EM, de Wijkerslooth TR, Lansdorp-Vogelaar I, et al. Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. United European Gastroenterol J. 2017;5(3):448–54.

24. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167–75.

25. Streett SE. Endoscopic colorectal cancer screening in women: can we do better? Gastrointest Endosc. 2007;65(7):1047–9.

26. Witte TN, Enns R. The difficult colonoscopy. Can J Gastroenterol. 2007;21(8):487–90.

27. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med. 2018;168(11):775–82.

28. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12.

661 29. DeWeerdt S. Microbiome: Microbial mystery. Nature. 2015;521(7551):S10–1.

662 30. Garrett WS. The gut microbiota and colon cancer. Science. 2019;364(6446):1133–5.

663 31. Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev
664 Clin Oncol. 2023;20(7):429–52.

665 32. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical
666 applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690–704.

667 33. Janney A, Powrie F, Mann EH. Host-microbiota maladaptation in colorectal cancer.
668 Nature. 2020;585(7826):509–17.

669 34. Xing C, Du Y, Duan T, Nim K, Chu J, Wang HY, et al. Interaction between microbiota and
670 immunity and its implication in colorectal cancer. Front Immunol. 2022;13:963819.

671 35. Chen Y, Chen YX. Microbiota-Associated Metabolites and Related Immunoregulation in
672 Colorectal Cancer. Cancers (Basel). 2021;13(16):4054.

673 36. Zheng DP, Liwinski T, Elinav E. Interaction between microbiota and immunity in health
674 and disease. Cell Res. 2020;30(6):492–506.

675 37. Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal
676 cancer. Intest Res. 2018;16(3):338–45.

677 38. Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The Genus Alistipes: Gut
678 Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front Immunol.
679 2020;11:906.

680 39. Sanchez-Alcoholado L, Ordonez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, Medina
681 JA, et al. Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity
682 and Colorectal Cancer. Int J Mol Sci. 2020;21(18).

683 40. Wu Z, Huang Y, Zhang R, Zheng C, You F, Wang M, et al. Sex differences in colorectal
684 cancer: with a focus on sex hormone-gut microbiome axis. Cell Commun Signal. 2024;22(1):167.

685 41. Rodriguez-Santiago Y, Garay-Canales CA, Nava-Castro KE, Morales-Montor J. Sexual
686 dimorphism in colorectal cancer: molecular mechanisms and treatment strategies. Biol Sex Differ.
687 2024;15(1):48.

688 42. Zhou YL, Hong J. Gut microbiota: Guardians of the female gut health. Cancer Cell.
689 2023;41(8):1392–4.

690 43. Cheng WT, Kantilal HK, Davamani F. The Mechanism of Bacteroides fragilis Toxin
691 Contributes to Colon Cancer Formation. Malays J Med Sci. 2020;27(4):9–21.

692 44. Spigaglia P, Barbanti F, Germinario EAP, Criscuolo EM, Bruno G, Sanchez-Mete L, et al.
693 Comparison of microbiological profile of enterotoxigenic Bacteroides fragilis (ETBF) isolates from
694 subjects with colorectal cancer (CRC) or intestinal pre-cancerous lesions versus healthy
695 individuals and evaluation of environmental factors involved in intestinal dysbiosis. Anaerobe.
696 2023;82:102757.

697 45. Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N, et al. Western-Style Diet, pks
698 Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective
699 Cohort Studies. Gastroenterology. 2022;163(4):862–74.

700 46. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM,
701 Nomburg J, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli.
702 Nature. 2020;580(7802):269–73.

703 47. Sengupta S, Muir JG, Gibson PR. Does butyrate protect from colorectal cancer? J
704 Gastroenterol Hepatol. 2006;21(1 Pt 2):209–18.

705 48. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal
706 metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med.
707 2019;25(4):679–89.

708 49. Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, et al. Clostridium butyricum, a butyrate-
709 producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and
710 gut microbiota. Cancer Lett. 2020;469:456–67.

711 50. Zwezerijnen-Jiwa FH, Sivov H, Paizs P, Zafeiropoulou K, Kinross J. A systematic review
712 of microbiome-derived biomarkers for early colorectal cancer detection. Neoplasia.
713 2023;36:100868.

714 51. Fusco W, Bricca L, Kaitsas F, Tartaglia MF, Venturini I, Rugge M, et al. Gut microbiota in
715 colorectal cancer: From pathogenesis to clinic. Best Pract Res Clin Gastroenterol.
716 2024;72:101941.

717 52. Birkeland EE, Kvaerner AS, Avershina E, Bucher-Johannessen C, Bemanian V, Blix HS,
718 et al. Microbiome signatures for detection of colorectal lesions in population-based FIT screening.
719 medRxiv [Preprint]. 2025.

720 53. Valeri F, Endres K. How biological sex of the host shapes its gut microbiota. Front
721 Neuroendocrinol. 2021;61:100912.

722 54. Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome
723 revealed: sex differences in bidirectional interactions between the microbiota, hormones,
724 immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265–75.

725 55. Yoon K, Kim N. Roles of Sex Hormones and Gender in the Gut Microbiota. J
726 Neurogastroenterol Motil. 2021;27(3):314–25.

727 56. Thackray VG. Sex, Microbes, and Polycystic Ovary Syndrome. Trends Endocrinol Metab.
728 2019;30(1):54–65.

729 57. Kvaerner AS, Birkeland E, Bucher-Johannessen C, Vinberg E, Nordby JI, Kangas H, et
730 al. The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the
731 gut microbiome in colorectal cancer screening participants. BMC cancer. 2020.

732 58. Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, et al. Colorectal Cancer
733 Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results
734 From a Randomized Trial. Gastroenterology. 2021;160(4):1085–96 e5.

735 59. Andersen LF, Solvoll K, Johansson LR, Salminen I, Aro A, Drevon CA. Evaluation of a
736 food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose
737 tissue and serum. American journal of epidemiology. 1999;150(1):75–87.

738 60. Andersen LF, Tomten H, Haggarty P, Lovo A, Hustvedt BE. Validation of energy intake
739 estimated from a food frequency questionnaire: a doubly labelled water study. Eur J Clin Nutr.
740 2003;57(2):279–84.

741 61. Andersen LF, Veierod MB, Johansson L, Sakhi A, Solvoll K, Drevon CA. Evaluation of
742 three dietary assessment methods and serum biomarkers as measures of fruit and vegetable
743 intake, using the method of triads. Br J Nutr. 2005;93(4):519–27.

744 62. Carlsen MH, Lillegaard IT, Karlsen A, Blomhoff R, Drevon CA, Andersen LF. Evaluation
745 of energy and dietary intake estimates from a food frequency questionnaire using independent
746 energy expenditure measurement and weighed food records. Nutr J. 2010;9(1):37.

747 63. Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, et al.
748 Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a
749 biomarker in breast cancer patients during treatment. Nutr J. 2018;17(1):94.

750 64. Nes M, Frost Andersen L, Solvoll K, Sandstad B, Hustvedt BE, Lovo A, et al. Accuracy of
751 a quantitative food frequency questionnaire applied in elderly Norwegian women. Eur J Clin Nutr.
752 1992;46(11):809–21.

753 65. Norwegian Food Safety Authority. Norwegian Food Composition Database 2019
754 [Internet]. 2019 [cited 2025 20.02]. Available from: www.matvaretabellen.no.

755 66. Shams-White MM, Brockton NT, Mitrou P, Romaguera D, Brown S, Bender A, et al.
756 Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research
757 (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. Nutrients.
758 2019;11(7).

759 67. Shams-White MM, Romaguera D, Mitrou P, Reedy J, Bender A, Brockton NT. Further
760 Guidance in Implementing the Standardized 2018 World Cancer Research Fund/American
761 Institute for Cancer Research (WCRF/AICR) Score. Cancer Epidemiology Biomarkers &
762 Prevention. 2020;29(5):889–94.

763 68. Kvaerner AS, Andersen AR, Henriksen HB, Knudsen MD, Johansen AMW, Hjartaker A,
764 et al. Associations of the 2018 World Cancer Research Fund/American Institute of Cancer
765 Research (WCRF/AICR) cancer prevention recommendations with stages of colorectal
766 carcinogenesis. Cancer Med. 2023;12(13):14806–19.

767 69. WHO. Collaborating centre for drug statistics methodology. ATC index with DDDs. Oslo:
768 WHO. 1997.

769 70. Istvan P, Birkeland E, Avershina E, Kvaerner AS, Bemanian V, de Vos W, et al. Exploring
770 the gut virome in fecal immunochemical test stool samples reveals novel associations with
771 lifestyle in a large population-based study. medRxiv. 2023:2023.08. 24.23294548.

772 71. Rounge TB, Meisal R, Nordby JI, Ambur OH, de Lange T, Hoff G. Evaluating gut
773 microbiota profiles from archived fecal samples. BMC Gastroenterol. 2018;18(1):171.

72. Blanco-Miguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol. 2023;41(11):1633–44.

73. Beghini F, McIver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife. 2021;10.

74. Wang Y, Wang Q, Huang H, Huang W, Chen Y, McGarvey PB, et al. A crowdsourcing open platform for literature curation in UniProt. PLoS Biol. 2021;19(12):e3001464.

75. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.

76. Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. Gene Ontology Consortium. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1).

77. Piccinno G, Thompson KN, Manghi P, Ghazi AR, Thomas AM, Blanco-Miguez A, et al. Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer. Nat Med. 2025;31(7):2416–29.

78. Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. Journal of statistical software. 2011;45:1–67.

79. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin P, O'Hara R, et al. Vegan: community ecology package. Ordination methods, diversity analysis and other functions for community and vegetation ecologists. 2015:2.3–1.

80. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021;17(11):e1009442.

81. Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, François R, et al. Welcome to the Tidyverse. Journal of open source software. 2019;4(43):1686.

82. Kassambara A. rstatix: Pipe-friendly framework for basic statistical tests. R package version 06 0. 2020.

83. Venables WN, Ripley BD. Modern applied statistics with S-PLUS: Springer Science & Business Media; 2013.

84. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019;25(4):667–78.

85. Young C, Wood HM, Fuentes Balaguer A, Bottomley D, Gallop N, Wilkinson L, et al. Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy. Clin Cancer Res. 2021;27(8):2246–54.

809 86. Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic
810 and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in
811 colorectal cancer. Nat Med. 2019;25(6):968–76.

812 87. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and
813 colorectal cancer: a meta-analysis. JAMA. 2008;300(23):2765–78.

814 88. Bailie L, Loughrey MB, Coleman HG. Lifestyle risk factors for serrated colorectal polyps:
815 a systematic review and meta-analysis. Gastroenterology. 2017;152(1):92–104.

816 89. Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund/American
817 institute for cancer research third expert report on diet, nutrition, physical activity, and cancer:
818 impact and future directions. The Journal of nutrition. 2020;150(4):663–71.

819 90. Kvaerner AS, Birkeland E, Vinberg E, Hoff G, Hjartaker A, Rounge TB, et al. Associations
820 of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr.
821 2023;129(12):2122–32.

822 91. Kvaerner AS, Birkeland E, Avershina E, Botteri E, Bucher-Johannessen C, Dines Knudsen
823 M, et al. The association between alcohol consumption and colorectal carcinogenesis is partially
824 mediated by the gut microbiome. medRxiv [Preprint]. 2024:2024.10. 17.24315656.

825 92. Knudsen MD, Kvaerner AS, Botteri E, Holme O, Hjartaker A, Song M, et al. Lifestyle
826 predictors for inconsistent participation to fecal based colorectal cancer screening. BMC cancer.
827 2022;22(1):172.

828 93. Knudsen MD, Botteri E, Holme O, Hjartaker A, Song M, Thiis-Evensen E, et al. Association
829 between lifestyle and site-specific advanced colorectal lesions in screening with faecal
830 immunochemical test and sigmoidoscopy. Dig Liver Dis. 2021;53(3):353–9.

831 94. Joo HJ, Lee HS, Jang BI, Kim DB, Kim JH, Park JJ, et al. Sex-specific differences in
832 colorectal cancer: A multicenter retrospective cohort study. Cancer Reports. 2023;6(8):e1845.

833 95. Niedermaier T, Heisser T, Gies A, Guo F, Amitay EL, Hoffmeister M, et al. To what extent
834 is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results
835 from a large German screening population. Intl Journal of Cancer. 2021;149(11):1877–86.

836 96. Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, et al. Effect of Sex, Age,
837 and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and
838 Meta-analysis. Gastroenterology. 2019;157(6):1494–505.

839 97. Zhang X, Zhong H, Li Y, Shi Z, Ren H, Zhang Z, et al. Sex- and age-related trajectories of
840 the adult human gut microbiota shared across populations of different ethnicities. Nat Aging.
841 2021;1(1):87–100.

842 98. Li Q, Chan H, Liu WX, Liu CA, Zhou Y, Huang D, et al. Carnobacterium maltaromaticum
843 boosts intestinal vitamin D production to suppress colorectal cancer in female mice. Cancer Cell.
844 2023;41(8):1450–65 e8.

845 99. Song CH, Kim N, Nam RH, Choi SI, Lee HN, Surh YJ. 17beta-Estradiol supplementation
846 changes gut microbiota diversity in intact and colorectal cancer-induced ICR male mice. Scientific
847 reports. 2020;10(1):12283.

848 100. Bucher-Johannessen C, Senthakumaran T, Avershina E, Birkeland E, Hoff G, Bemanian
849 V, et al. Species-level verification of Phascolarctobacterium association with colorectal cancer.
850 mSystems. 2024;9(10):e0073424.

851 101. Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P, et al.
852 Long-term follow-up of colorectal cancer screening attendees identifies differences in
853 Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing. Front Oncol.
854 2023;13:1183039.

855 102. Senthakumaran T, Moen AEF, Tannaes TM, Endres A, Brackmann SA, Rounge TB, et al.
856 Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in
857 cancers, adenomatous polyps, and healthy controls. Eur J Clin Microbiol Infect Dis.
858 2023;42(3):305–22.

859 103. Hua H, Sun Y, He X, Chen Y, Teng L, Lu C. Intestinal Microbiota in Colorectal Adenoma-
860 Carcinoma Sequence. Front Med (Lausanne). 2022;9:888340.

861 104. Doden HL, Pollet RM, Mythen SM, Wawrzak Z, Devendran S, Cann I, et al. Structural and
862 biochemical characterization of 20beta-hydroxysteroid dehydrogenase from Bifidobacterium
863 adolescentis strain L2-32. The Journal of biological chemistry. 2019;294(32):12040–53.

864 105. Sinha T, Vich Vila A, Garmaeva S, Jankipersadsing SA, Imhann F, Collij V, et al. Analysis
865 of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes.
866 2019;10(3):358–66.

867 106. McCurry MD, D'Agostino GD, Walsh JT, Bisanz JE, Zalosnik I, Dong X, et al. Gut bacteria
868 convert glucocorticoids into progestins in the presence of hydrogen gas. Cell.
869 2024;187(12):2952–68 e13.

870 107. Jiang L, Fei H, Tong J, Zhou J, Zhu J, Jin X, et al. Hormone Replacement Therapy
871 Reverses Gut Microbiome and Serum Metabolome Alterations in Premature Ovarian
872 Insufficiency. Front Endocrinol (Lausanne). 2021;12:794496.

873 108. Liao H, Li C, Ai Y, Kou Y. Gut microbiome is more stable in males than in females during
874 the development of colorectal cancer. J Appl Microbiol. 2021;131(1):435–48.

875 109. Yang X, Li P, Qu Z, Zhuang J, Wu Y, Wu W, et al. Gut bacteria and sex differences in
876 colorectal cancer. J Med Microbiol. 2023;72(6).

877 110. Song CH, Kim N, Nam RH, Choi SI, Jang JY, Kim EH, et al. The Possible Preventative
878 Role of Lactate- and Butyrate-Producing Bacteria in Colorectal Carcinogenesis. Gut Liver.
879 2024;18(4):654–66.

880 111. Yu S, Chu J, Wu Y, Zhuang J, Qu Z, Song Y, et al. Third-generation PacBio sequencing
881 to explore gut bacteria and gender in colorectal cancer. Microb Pathog. 2024;192:106684.

882 112. Wang SY, Dong XT, Yuan Z, Jin LX, Gao WF, Han YK, et al. Factors associated with false
883 fecal immunochemical test results in colorectal cancer screening. World J Gastrointest Oncol.
884 2025;17(4):101487.

885 113. Whang A, Nagpal R, Yadav H. Bi-directional drug-microbiome interactions of anti-
886 diabetics. EBioMedicine. 2019;39:591–602.

887 114. Gaab ME, Lozano PO, Ibanez D, Manese KD, Riego FM, Tiongco RE, et al. A Meta-
888 Analysis on the Association of Colibactin-Producing pks+ Escherichia coli with the Development
889 of Colorectal Cancer. Lab Med. 2023;54(1):75–82.

890 115. de Klaver W, de Wit M, Bolijn A, Tijssen M, Delis-van Diemen P, Lemmens M, et al.
891 Polyketide synthase positive Escherichia coli one-time measurement in stool is not informative of
892 colorectal cancer risk in a screening setting. J Pathol. 2024;263(2):217–25.

893 116. Lattanzi G, Perillo F, Diaz-Basabe A, Caridi B, Amoroso C, Baeri A, et al. Estrogen-related
894 differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of
895 colorectal cancer. Oncoimmunology. 2024;13(1):2425125.

896 117. Berthelsen M, Berstad P, Randel KR, Hoff G, Natvig E, Holme O, et al. The impact of
897 driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal
898 immunochemical blood test. Cancer Epidemiol. 2022;80:102244.

899 118. Botteri E, Hoff G, Randel KR, Holme O, de Lange T, Bernklev T, et al. Characteristics of
900 nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and
901 faecal immunochemical testing. Int J Cancer. 2022;151(3):361–71.